Logo image of PXMD

PAXMEDICA INC (PXMD) Stock Price, Quote, News and Overview

NASDAQ:PXMD - Nasdaq - US70424C2035 - Common Stock - Currency: USD

0.6883  -0.06 (-7.61%)

After market: 0.37 -0.32 (-46.24%)

PXMD Quote, Performance and Key Statistics

PAXMEDICA INC

NASDAQ:PXMD (5/1/2024, 8:18:16 PM)

After market: 0.37 -0.32 (-46.24%)

0.6883

-0.06 (-7.61%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High29.75
52 Week Low0.37
Market Cap5.10M
Shares7.41M
Float6.81M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2024-05-13
IPO08-19 2022-08-19


PXMD short term performance overview.The bars show the price performance of PXMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40 -60

PXMD long term performance overview.The bars show the price performance of PXMD in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PXMD is 0.6883 USD. In the past month the price increased by 27.7%. In the past year, price decreased by -97.28%.

PAXMEDICA INC / PXMD Daily stock chart

PXMD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.53 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.62 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.81 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About PXMD

Company Profile

PXMD logo image PaxMedica Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tarrytown, New York and currently employs 3 full-time employees. The company went IPO on 2022-08-19. PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The firm is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Company Info

PAXMEDICA INC

303 South Broadway, Suite 125

Tarrytown NEW YORK US

Employees: 3

Company Website: https://www.paxmedica.com/

Phone: 19149872876

PAXMEDICA INC / PXMD FAQ

What is the stock price of PAXMEDICA INC today?

The current stock price of PXMD is 0.6883 USD. The price decreased by -7.61% in the last trading session.


What is the ticker symbol for PAXMEDICA INC stock?

The exchange symbol of PAXMEDICA INC is PXMD and it is listed on the Nasdaq exchange.


On which exchange is PXMD stock listed?

PXMD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PAXMEDICA INC stock?

null analysts have analysed PXMD and the average price target is 3.06 USD. This implies a price increase of 344.57% is expected in the next year compared to the current price of 0.6883. Check the PAXMEDICA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PAXMEDICA INC worth?

PAXMEDICA INC (PXMD) has a market capitalization of 5.10M USD. This makes PXMD a Nano Cap stock.


How many employees does PAXMEDICA INC have?

PAXMEDICA INC (PXMD) currently has 3 employees.


What are the support and resistance levels for PAXMEDICA INC (PXMD) stock?

PAXMEDICA INC (PXMD) has a support level at 0.68 and a resistance level at 0.75. Check the full technical report for a detailed analysis of PXMD support and resistance levels.


Should I buy PAXMEDICA INC (PXMD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PAXMEDICA INC (PXMD) stock pay dividends?

PXMD does not pay a dividend.


When does PAXMEDICA INC (PXMD) report earnings?

PAXMEDICA INC (PXMD) will report earnings on 2024-05-13.


What is the Price/Earnings (PE) ratio of PAXMEDICA INC (PXMD)?

PAXMEDICA INC (PXMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.85).


What is the Short Interest ratio of PAXMEDICA INC (PXMD) stock?

The outstanding short interest for PAXMEDICA INC (PXMD) is 0.01% of its float. Check the ownership tab for more information on the PXMD short interest.


PXMD Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to PXMD. When comparing the yearly performance of all stocks, PXMD is a bad performer in the overall market: 88.21% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PXMD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PXMD. The financial health of PXMD is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PXMD Financial Highlights

Over the last trailing twelve months PXMD reported a non-GAAP Earnings per Share(EPS) of -15.85. The EPS increased by 23.95% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -321.98%
ROE -540.3%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%79.11%
Sales Q2Q%N/A
EPS 1Y (TTM)23.95%
Revenue 1Y (TTM)N/A

PXMD Ownership and Analysts


Ownership
Inst Owners0%
Ins Owners100.3%
Short Float %0.01%
Short Ratio0
Analysts
AnalystsN/A
Price Target3.06 (344.57%)
EPS Next Y88.34%
Revenue Next YearN/A